{"filing":{"accession_number":"0001708599-26-000048","cik":"0001708599","ticker":"SER","company_name":"Serina Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ser-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813.htm"},"events":[{"id":27629,"run_id":25194,"accession_number":"0001708599-26-000048","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release issued on August 13, 2026. The Item 2.02 section explicitly states \"the Company issued a press release announcing its financial results for the quarter ended June 30, 2026,\" and the exhibit includes condensed consolidated balance sheets, statements of operations, and cash flows. This is a standard earnings release disclosure material to investors assessing the registrant's financial condition and operational performance.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29220,"accession_number":"0001708599-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release issued on August 13, 2026. The Item 2.02 section explicitly states \"the Company issued a press release announcing its financial results for the quarter ended June 30, 2026,\" and the exhibit includes condensed consolidated balance sheets, statements of operations, and cash flows. This is a standard earnings release disclosure material to investors assessing the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:04:39.895040+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29220,"accession_number":"0001708599-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release issued on August 13, 2026. The Item 2.02 section explicitly states \"the Company issued a press release announcing its financial results for the quarter ended June 30, 2026,\" and the exhibit includes condensed consolidated balance sheets, statements of operations, and cash flows. This is a standard earnings release disclosure material to investors assessing the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:04:39.895040+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-08-13"}]}